Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis
Full story
Lynk Pharmaceuticals announced that the NMPA formally accepted a New Drug Application for zemprocitinib capsules. The drug is intended to treat moderate-to-severe active rheumatoid arthritis. The company focuses on immune and inflammatory diseases.
SHANGHAI and HANGZHOU, China and BOSTON, Nov. 6, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (“Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe active rheumatoid arthritis (RA) was formally accepted by […]